Registry-listed formulations

Arformoterol tartrate · chembl:CHEMBL1951071

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

19 source entries across 10 studies. This list may not include all unresolved or historical entries.

  • arformoterol tartrate inhalation solutionRegistry intervention

    Molecular identity unconfirmed

    View study and source
  • arformoterol tartrate inhalation solutionRegistry intervention

    Molecular identity unconfirmed

    View study and source
  • arformoterol tartrate inhalation solutionRegistry intervention

    Molecular identity unconfirmed

    View study and source
  • Arformoterol tartrate inhalation solutionRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • Arformoterol Tartrate Inhalation SolutionRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • Arformoterol Tartrate Inhalation SolutionRegistry intervention

    Molecular identity unconfirmed

    View study and source
  • Arformoterol Tartrate Inhalation SolutionRegistry intervention

    Molecular identity unconfirmed

    View study and source
  • Arformoterol tartrate inhalation solutionRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • Arformoterol tartrate inhalation solutionRegistry intervention

    Molecular identity unconfirmed

    View study and source
  • Arformoterol tartrate inhalation solutionRegistry intervention

    Molecular identity unconfirmed

    View study and source
  • Arformoterol tartrate inhalation solutionRegistry intervention

    Molecular identity unconfirmed

    View study and source
  • Arformoterol tartrate inhalation solutionRegistry intervention

    Molecular identity unconfirmed

    View study and source
  • Arformoterol tartrate inhalation solutionRegistry intervention

    Molecular identity unconfirmed

    View study and source
  • Arformoterol tartrate inhalation solutionRegistry intervention

    Molecular identity unconfirmed

    View study and source
  • Arformoterol tartrate inhalation solutionRegistry intervention

    Molecular identity unconfirmed

    View study and source
  • Arformoterol tartrate inhalation solutionRegistry intervention

    Molecular identity unconfirmed

    View study and source
  • AformoterolRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • Arformoterol tartrate inhalation solutionRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • BrovanaRegistry intervention

    Linked study entry; product equivalence not established

    View study and source

Success Metrics

Clinical Success Rate
100.0%

Based on 9 completed trials

Completion Rate
82%(9/11)
Active Trials
0(0%)
Results Posted
78%(7 trials)
Terminated
2(18%)

Phase Distribution

Not Applicable
1
9%
Phase 4
5
45%
Phase 2
2
18%
Phase 3
3
27%

Phase Distribution

0

Early Stage

2

Mid Stage

8

Late Stage

Phase Distribution11 total trials
Phase 2Efficacy & side effects
2(18.2%)
Phase 3Large-scale testing
3(27.3%)
Phase 4Post-market surveillance
5(45.5%)
N/ANon-phased studies
1(9.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

81.8%

9 of 11 finished

Non-Completion Rate

18.2%

2 ended early

Currently Active

0

trials recruiting

Total Trials

11

all time

Status Distribution
Completed(9)
Terminated(2)

Detailed Status

Completed9
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
11
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 22 (18.2%)
Phase 33 (27.3%)
Phase 45 (45.5%)
N/A1 (9.1%)

Trials by Status

terminated218%
completed982%

Recent Activity

0 active trials
Showing 5 of 11
terminatedphase_4

Nebulizer Versus Dry Powdered Inhalers for Chronic Obstructive Pulmonary Disease (COPD)

NCT03219866
terminatedphase_4

A Study of Arformoterol Tartrate Inhalation Solution and Tiotropium Bromide on Re-hospitalization in Chronic Obstructive Pulmonary Disease (COPD) Subjects

NCT02275481
completedphase_4

Effect of Bronchodilation on Cycle vs Treadmill Exercise Endurance Time in COPD

NCT00754546
completedphase_3

A Pivotal Study of the Safety and Effectiveness of Arformoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT00685841
completednot_applicable

Assessment of Arformoterol for Chronic Obstructive Pulmonary Disease (COPD) Using Hyperpolarized 3He MRI

NCT00846287
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT03219866Phase 4

Nebulizer Versus Dry Powdered Inhalers for Chronic Obstructive Pulmonary Disease (COPD)

Terminated
NCT02275481Phase 4

A Study of Arformoterol Tartrate Inhalation Solution and Tiotropium Bromide on Re-hospitalization in Chronic Obstructive Pulmonary Disease (COPD) Subjects

Terminated
NCT00754546Phase 4

Effect of Bronchodilation on Cycle vs Treadmill Exercise Endurance Time in COPD

Completed
NCT00685841Phase 3

A Pivotal Study of the Safety and Effectiveness of Arformoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Completed
NCT00846287Not Applicable

Assessment of Arformoterol for Chronic Obstructive Pulmonary Disease (COPD) Using Hyperpolarized 3He MRI

Completed
NCT00250679Phase 3

Safety and Efficacy of Arformoterol Tartrate Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease

Completed
NCT00424528Phase 4

Efficacy Safety Study of Arformoterol/Tiotropium Combination Versus Either Therapy Alone in Chronic Obstructive Pulmonary Disease (COPD)

Completed
NCT00064402Phase 3

Determine the Safety and Efficacy of (R,R)-Formoterol in the Treatment of Subjects With COPD

Completed
NCT00571428Phase 4

Efficacy Safety Study of Arformoterol QD Dosing Versus BID Dosing in COPD

Completed
NCT00685529Phase 2

Study of Arformoterol Tartrate Inhalation Solution and Racemic Formoterol in Subjects With Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)

Completed
NCT00691405Phase 2

A Dose Ranging Study of Arformoterol Given Once Daily Compared to Arformoterol Given Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Completed

All 11 trials loaded

Drug Details

Intervention Type
Drug
Molecule Type
Small molecule
Total Trials
11

External References

ChEMBL
CHEMBL1951071

Names & Codes

Trade Names

brovana